Topic:

Financials

Latest Headlines

Latest Headlines

Sorin invests $20M in implantable respiratory device startup Respicardia

Cardiovascular device company Sorin Group has invested $20 million in Respicardia. The financing is to be used to fund ongoing clinical testing of the startup's remede System, which is a pacemaker-like device for central sleep apnea that delivers electrical pulses via an implantable lead to the phrenic nerve.

Illumina up 10% on strongest growth since 2011, raises 2014 guidance

Genomic sequencing seems to have come of age with Illumina as a substantial driver and beneficiary. During the third quarter, the company achieved astonishing revenue growth of 35% to $481 million over the same quarter last year.

Google, KKR, Kleiner Perkins invest $542M in virtual reality eyeglass startup

As med tech companies set their sights on wearable technology with 3-D imaging capabilities, a Florida startup brought in $542 million in VC funding to develop its innovative eyeglasses-like device that could provide a new interface for patient-doctor communication.

Medrobotics raises $20M to pursue FDA approval, EU marketing

Medrobotics, a surgical products company focused on medical robotics, raised $20 million in equity financing.

Veran raised $12M to commercialize lung biopsy device

St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.

Philips looks to HealthTech acquisitions, as it slips on manufacturing, IP difficulties

Philips shed as much as 4% in early trading as continued manufacturing problems and intellectual property litigation as well as weakness in Russia and China weighed on investor confidence after it reported third-quarter results.

Big CROs are booming, but can it last?

The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry.

UPDATED: Thumbing its nose at critics, Valeant touts Q3 growth, hikes forecasts

Valeant may have upped its Q3 revenue by 33% and beat analysts' bottom-line expectations--not to mention hiked its forecast for this year and next. But takeover target Allergan still isn't impressed. On the other hand, shareholders might be if Valeant hikes its hostile bid again, as its CEO now suggests.

Blaze wins NCI funding for 'tumor paint' after successful dog study

Blaze Bioscience has nabbed a $1.5 million Small Business Innovation Research (SBIR) Phase II award from the National Cancer Institute (NCI) to continue researching its product, called Tumor Paint BLZ-100, which will be studied in people with soft tissue sarcoma. The company was awarded the funding based on the successful completion of a trial in 27 pet dogs with various tumor types.

Stryker to repatriate $2B, ready for acquisitions in 2H15

Stryker took an earnings hit during the third quarter, in part to repatriate $2 billion in cash for acquisitions and to establish an EU regional headquarters in Amsterdam, where it has moved some intellectual property. The IP transfer is expected to reduce its effective tax rate from an expected 22% in 2014 to 20% next year.